News

These data on the preventive migraine treatment confirmed findings from previous studies, with eptinezumab not only reducing total migraine days, but elongating the duration of consecutive migraine-free days.

Treatment with CBD resulted in a significant number of patients with TSC reporting being “much” or “very much” improved on the Subject/Caregiver Global Impression of Change.

The COMT inhibitor helps increase ON time without promoting dyskinesia.

The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed his experience with Zogenix’s investigational Dravet syndrome treatment in clinical trials and in the Expanded Access Program.

Data from the OVERCOME study of more than 20,000 respondents suggest that those whose acute migraine treatment was optimized according to the mTOQ had less disability and better quality of life.

Ofatumumab, Novartis’s fully human anti-CD20 monoclonal antibody, demonstrated a reduction in the risk of 3- and 6-month confirmed disability progression compared to teriflunomide in relapsing multiple sclerosis.

Neurology News Network for the week ending April 25, 2020.

The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed the real-world data collected from the Expanded Access Program for fenfluramine (Fintepla; Zogenix) in patients with Dravet syndrome.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 24, 2020.

Biohaven’s acute migraine treatment rimegepant showed numerically significant differences from placebo on pain relief, with benefit as early as 15 minutes postdose.

The neurologist at the Barrow Neurological Institute discussed her experience with telemedicine and gave advice on how to conduct examinations through audio/video platforms.

The initial report of the US Expanded Access Program for fenfluramine indicates that those with Dravet syndrome treated with fenfluramine (Fintepla; Zogenix) have clinically meaningful responses similar to that observed in clinical trials.

Data confirmed the prior results of the PROMISE-1 and PROMISE-2 studies, indicating the preventive effect on migraine with eptinezumab begins as early as day 1 post-infusion.

The drug's impact on neuroinflammation and neurodegeneration in the brain and spinal cord are currently being explored.

The professor of neurology at the University of Vermont Larner College of Medicine detailed what lessons and highlights he’s learned from shifting his migraine care to a telemedicine-based model during the COVID-19 pandemic.

Five-year EXPAND study data suggest that Novartis’s S1P receptor modulator has sustained benefit and delays disability over long-term treatment in patients with SPMS.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine offered her insight on how telemedicine is being utilized to help diagnose and treat sleep disorders amidst COVID-19.

The Novartis agent showed significant reduction of migraine days in both the real-world TELESCOPE and PERISCOPE studies in patients with migraine.

The professor of neurology at the University of Vermont Larner College of Medicine discussed the response from payers and physicians to the special article he and colleagues published in the journal Headache.

Researchers found multiple measure correlations between perampanel use and reductions in Insomnia Severity Index scores in those who had comorbid epilepsy and anxiety.